MLCS Quantification in Parkinson's Disease

V2, Crosslink

🧫

MLCS Quantification in Parkinson's Disease

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-mlcs-qua

🧫 Experiment Protocol Validationproposed

SUMMARY

# MLCS Quantification in Parkinson's Disease ## Background and Rationale Mitochondria-lysosome contact sites (MLCS) represent a critical and relatively recently discovered cellular interface that orchestrates fundamental neuronal homeostatic processes essential for neuronal survival and function. These dynamic membrane contact sites, which constitute approximately 5-20% of the mitochondrial surface in healthy neurons, serve as platforms for coordinating mitochondrial quality control, lipid metab

METHODOLOGY NOTES

**Phase 1: iPSC Derivation and Dopaminergic Neuronal Differentiation** Obtain CD34+ hematopoietic stem cells or fibroblasts from 5 Parkinson's Disease patients (mean age 60±8 years, Hoehn-Yahr stage 2-3, confirmed diagnosis) and 3 age-matched healthy controls. Reprogram to iPSCs using Sendai virus-based delivery of OCT4, SOX2, KLF4, and c-MYC. Maintain iPSC colonies in mTeSR Plus medium on Matrigel-coated dishes. Perform karyotyping and pluripotency validation via immunofluorescence (OCT4, NANOG, SOX2) and flow cytometry. Differentiate iPSCs to midbrain dopaminergic neurons following established dual-SMAD inhibition protocol: Day 0-3, culture in neural induction medium containing LDN193189 and SB431542; Day 3-10, add FGF8, CHIR99021, and purmorphamine; Day 10-25, supplement with GDNF, BDNF, and cAMP. Achieve ≥65% TUJ1+/MAP2+/TH+ dopaminergic neurons by Day 25 (assessed via high-content screening of ≥10,000 cells per line). Mature neurons for additional 10 days on poly-D-lysine/laminin-

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.896868Z'}
summary	# MLCS Quantification in Parkinson's Disease ## Background and Rationale Mitochondria-lysosome contact sites (MLCS) represent a critical and relatively recently discovered cellular interface that orch
entities	{'genes': ['FOXO1/MCU/MIRO1'], 'diseases': ["Parkinson's Disease"]}
model_system	human
_schema_version	1
experiment_type	validation
primary_outcome	Quantitatively characterize the structural and molecular alterations in mitochondria-lysosome contact sites that distinguish Parkinson's Disease neuronal systems from healthy neuronal controls
methodology_notes	Phase 1: iPSC Derivation and Dopaminergic Neuronal Differentiation Obtain CD34+ hematopoietic stem cells or fibroblasts from 5 Parkinson's Disease patients (mean age 60±8 years, Hoehn-Yahr stage 2
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.896878', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

733

Outgoing

678

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

MLCS Quantification in Parkinson's Disease

derives from (16)

supports (33)

💬 Discussion